CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma: First, mogamulizumab has been approved in Japan for relapsed or refractory CCR4+ adult T-cell leukemia-lymphoma (2012), PTCL (2014), and CTCL (2014) (35).